

**September 2, 2025**

 **Multiple Changes and Additions to High-Cost Specialty Drug (BIO) Coverage**

The following high-cost specialty (BIO) drugs will be reinsured effective 10/01/2025:

* Livmarli - An ileal bile acid transporter inhibitor indicated for:
* The treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome; and
* The treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis.
* Vyvgart - A neonatal Fc receptor blocker given as an infusion indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
* Vijoice - A kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.

\*Note: Vyvgart Hytrulo is not covered under the reinsurance program.

Elevidys has been reinstated as a covered service and reinsured effective 07/28/2025

The following high-cost specialty (BIO) drug will be covered under the reinsurance program effective 08/27/2025:

* Ryoncil - An allogeneic, off-the-shelf, bone marrow–derived mesenchymal stromal cell therapy indicated for the treatment of pediatric patients aged 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft-versus-host disease.

Retroactive requests for Ryoncil for reinsurance will be accepted until 09/30/2025.

Drugs Reinsurance Status Changing:

Syprine will no longer be covered under the reinsurance program effective 10/01/2025.